PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2015 | 2 | 3 | 197-201
Article title

Neowaskularyzacja naczyniówkowa w krótkowzroczności degeneracyjnej – skuteczność leczenia ranibizumabem (opis przypadku)

Content
Title variants
EN
Choroidal neovascularization in degenerative myopia – efficacy of ranibizumab therapy (case report)
Languages of publication
PL
Abstracts
EN
A case report of myopic choroidal neovascularization in 42-year old man treated with ranibizumab.
PL
Neowaskularyzacja naczyniówkowa to jedno z powikłań krótkowzroczności degeneracyjnej. W artykule opisano przypadek 42-letniego pacjenta leczonego ranibizumabem.
Discipline
Publisher

Journal
Year
Volume
2
Issue
3
Pages
197-201
Physical description
Contributors
  • Oddział Okulistyczny, Specjalistyczny Szpital im. dra Alfreda Sokołowskiego w Wałbrzychu
author
  • Oddział Okulistyczny, Specjalistyczny Szpital im. dra Alfreda Sokołowskiego w Wałbrzychu
  • Oddział Okulistyczny, Specjalistyczny Szpital im. dra Alfreda Sokołowskiego w Wałbrzychu
References
  • 1. Kański J. Okulistyka kliniczna. Elsevier Urban and Partner, Wrocław 2011; 623-625.
  • 2. Neelam K, Cheung CM, Ohno-Matsui K, et al. Choroidal neovascularization in pathological myopia. Prog Retin Eye Res 2012; 31(5): 495-525.
  • 3. Wong TY, Ferreira A, Hughes R, et al. Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review. Am J Ophthalmol 2014; 157(1): 9-25.
  • 4. Wakabayashi T, Ikuno Y. Choroidal filling delay in choroidal neovascularisation due to pathological myopia. Br J Ophthalmol 2010; 94(5): 611-615.
  • 5. Leveziel N, Yu Y, Reynolds R, et al. Genetic factors for choroidal neovascularization associated with high myopia. Invest Ophthalmol Vis Sci 2012; 53(8): 5004-5009.
  • 6. Akagi-Kurashige Y, Kumagai K, Yamashiro K, et al. Vascular endothelial growth factor gene polymorphisms and choroidal neovascularization in highly myopic eyes. Invest Ophthalmol Vis Sci 2012; 53(4): 2349-2353.
  • 7. Miyake M, Yamashiro K, Nakanishi H, et al. Evaluation of pigment epithelium-derived factor and complement factor I polymorphisms as a cause of choroidal neovascularization in highly myopic eyes. Invest Ophthalmol Vis Sci 2013; 54(6): 4208- -4212.
  • 8. Blinder KJ, Blumenkranz MS, Bressler NM, et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial – VIP report no. 3. Ophthalmology 2003; 110: 667-673.
  • 9. Montero JA, Ruiz-Moreno JM. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study. Br J Ophthalmol 2007; 91: 131-133.
  • 10. Secretan M, Kuhn D, Soubrane G, Coscas G. Long term visual outcome of choroidal neovascularisation in pathologic myopia: natural history and laser treatment. Eur J Ophthalmol 1997; 7: 307-316.
  • 11. Hamelin N, Glacet-Bernard A, Brindeau C, et al. Surgical treatment of subfoveal neovascularisation in myopia: macular translocation vs surgical removal. Am J Ophthalmol 2002; 133: 530-536.
  • 12. Ruiz-Moreno JM, de la Vega C. Surgical removal of subfoveal choroidal neovascularisation in highly myopic patients. Br J Ophthalmol 2001; 85: 1041-1043.
  • 13. Mateo C, Moreno J, Rosales G, et al. Two-year results of macular translocation with sclera infolding in myopic choroidal neovascularisation. Semin Ophthalmol 2004; 19: 29-42.
  • 14. Charakterystyka produktu leczniczego – leku Lucentis – aneks I., Novartis Europharm Limited.
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-3f1dac11-0c25-49ed-84e4-29bbfc296ff7
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.